Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
First Claim
Patent Images
1. A method for treating a patient having epidermolysis bullosa simplex, comprising the step of administering to the patient a lysine derivative surfactant, wherein the lysine derivative surfactant comprises an alkanoyl substituent containing at least 8 carbon atoms bound to the α
- -nitrogen of the lysine, and further wherein the ε
-nitrogen of the lysine forms part of an isothiocyanate functional group.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers and/or activity modifiers.
-
Citations
8 Claims
-
1. A method for treating a patient having epidermolysis bullosa simplex, comprising the step of administering to the patient a lysine derivative surfactant, wherein the lysine derivative surfactant comprises an alkanoyl substituent containing at least 8 carbon atoms bound to the α
- -nitrogen of the lysine, and further wherein the ε
-nitrogen of the lysine forms part of an isothiocyanate functional group. - View Dependent Claims (2, 3, 4, 5, 6)
- -nitrogen of the lysine, and further wherein the ε
-
7. A method for treating a patient having epidermolysis bullosa simplex, consisting essentially of the step of administering to the patient a lysine derivative surfactant, wherein the lysine derivative surfactant comprises an alkanoyl substituent containing at least 8 carbon atoms bound to the α
- -nitrogen of the lysine, and further wherein the ε
-nitrogen of the lysine forms part of an isothiocyanate functional group.
- -nitrogen of the lysine, and further wherein the ε
-
8. A method for treating a patient having epidermolysis bullosa simplex, consisting of the step of administering to the patient a lysine derivative surfactant, wherein the lysine derivative surfactant comprises an alkanoyl substituent containing at least 8 carbon atoms bound to the α
- -nitrogen of the lysine, and further wherein the ε
-nitrogen of the lysine forms part of an isothiocyanate functional group.
- -nitrogen of the lysine, and further wherein the ε
Specification